5Wang M,Rule SA,Martin P,et al.Interim results of an international,multicenter,phase 2study of bruton's tyrosine kinase(BTK)inhibitor,Ibrutinib(PCI-32765),in relapsed or refractory mantle cell lymphoma(MCL):durable efficacy and tolerability with longer follow up[J].ASH Annual Meeting Abstracts,2012,120:904.
6Byrd JC,Furman RR,Coutre S,et al.The bruton's tyrosine kinase(BTK)inhibitor Ibrutinib(PCI-32765)promotes high response rate,durable remissions,and is tolerable in treatment naive(TN)and relapsed or refractory(RR)chronic lymphocytic leukemia(CLL)or small lymphocytic lymphoma(SLL)patients including patients with high-risk(HR)disease:new and updated results of 116 patients in a phase Ib/II study[J].ASH Annual Meeting Abstracts,2012,120:189.
7Wilson WH,Gerecitano JF,Goy A,et al.The bruton's tyrosine kinase(BTK)inhibitor,Ibrutinib(PCI-32765),has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma(DLBCL):interim results of a multicenter,open-label,phase 2study[J].ASH Annual Meeting Abstracts,2012,120:686.
8Friedberg JW,Vose JM,Kelly JL,et al.The combination of bendamustine,bortezomib,and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma[J].Blood,2011,117:2807-2812.
9Goy A,Bernstein SH,Kahl BS,et al.Bortezomib in patients with relapsed or refractory mantle cell lymphoma:updated time-to-event analyses of themulticenter phase 2 PINNACLE study[J].Ann Oncol,2009,20:520-525.
10Fisher RI,Bernstein SH,Kahl BS,et al.Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma[J].J Clin Oncol,2006,24:4867-4874.